At a dinner with reporters in San Francisco, OpenAI CEO Sam Altman spilled details on the company's ambitions beyond ChatGPT.

The company, which has been referred to as Merge Labs, is looking at an approach involving gene therapy that would modify ...

Microsoft (MSFT)-backed OpenAI's latest venture, Merge Labs, is looking to develop a novel gene therapy approach targeting brain cells. Read more here.

Sam Altman plans to support a brain computer interface startup to rival Neuralink, as OpenAI expands its AI and technology ...

The Trump administration has ended potential enforcement actions against dozens of tech firms and 165 corporations overall, ...

As stories pile up about disappointing or bizarre AI implementations, there are serious lessons to be learned from the ...

OpenAI CEO Sam Altman is reportedly working to launch a new brain-to-computer interface company, Merge Labs, with early ...

What if one man was quietly building the infrastructure to reshape civilization? From launching Mars colonization blueprints ...

The Austin American-Statesman is seeking an experienced business reporter to cover Elon Musk and his companies, their broad ...

Why Nvidia’s and AMD’s China deal with Trump could backfire. The companies making the most money from the AI boom are the ...

Inner speech — the internal monologue in your brain as you think about what to say — can be decoded by computers and might ...

The OpenAI CEO is planning to back new a brain-implant startup, Merge Labs, according to the Financial Times, citing ...